Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors

(2018) D. Ross Camidge et al.   Clinical Lung Cancer

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

(2018) Nicolas Girard   Future Oncology

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

(2017) Chih-Jen Yang et al.   BMC Pharmacology & Toxicology

Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials

(2016) J. C.-H. Yang et al.   ANNALS OF ONCOLOGY

Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases

(2016) Maximilian Hochmair et al.   ANTI-CANCER DRUGS

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

(2016) Daniel S.W. Tan et al.   Journal of Thoracic Oncology

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial

(2016) Yanzhe Zhu et al.   Thoracic Cancer

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2015) Amit Jain et al.   PLoS One

Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

(2014) Toshihiko Iuchi et al.   International Journal of Clinical Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of molecular testing methods for the detection ofEGFRmutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer

(2013) Fernando Lopez-Rios et al.   JOURNAL OF CLINICAL PATHOLOGY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

(2011) C. Grommes et al.   NEURO-ONCOLOGY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

(2010) Robert Pirker et al.   Journal of Thoracic Oncology